SAM
PLX icon

Smartleaf Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Smartleaf Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.3K Hold
25,975
– – ﹤0.01% 1413
2025
Q4 		$45.2K Buy
+25,975
New +$53.1K ﹤0.01% 1608

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Smartleaf Asset Management's PLX Position: Q1 2026 in Review

Smartleaf Asset Management held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 25,975 shares worth $54.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

Smartleaf Asset Management first reported a position in PLX in Q4 2025 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Smartleaf Asset Management held 25,975 shares of Protalix BioTherapeutics worth $54.3K as of Q1 2026.
  • Smartleaf Asset Management left its Protalix BioTherapeutics share count unchanged in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #1413 holding.
  • Smartleaf Asset Management first reported a position in Protalix BioTherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.